Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01

PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS

Ruth I. Geran, Nathaniel H. Greenberg, Marylea MacDonald et al. · Cancer chemotherapy reports. Part 1 · 1972 · 1.1K citations

Medicine, Medicinal Chemistry, Pharmacology +8

UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53

Qizhi Wang, Songqing Fan, Alan Eastman et al. · JNCI Journal of the National Cancer Institute · 1996 · 447 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.

Skipper He, Schabel Fm, Mellett Lb et al. · PubMed · 1970 · 285 citations

Medicine, Pharmacology, Toxicology +14

Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

Roderick T. Bunch, Alan Eastman · PubMed · 1996 · 221 citations

Medicine, Oncology, Pharmacology +17

Potential roles for preclinical pharmacology in phase I clinical trials.

Jerry M. Collins, Daniel S. Zaharko, Robert L. Dedrick et al. · PubMed · 1986 · 213 citations

Pharmacy, Pharmacokinetics, Pharmacology +14